Informations générales (source: ClinicalTrials.gov)
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
Interventional
N/A
Institut Curie (Voir sur ClinicalTrials)
septembre 2021
septembre 2027
02 décembre 2025
Sequential comparative prospective interventional study evaluating the impact of the use
of an optimization device of the decision of cancer treatment on aggressiveness of end of
life care. Comparison between a first period, period (A), of care as usual and a second
period, period (B), of systematic and iterative use of a device for optimizing the
decision to continue an anti-cancer treatment.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT CURIE | 10/04/2025 13:12:13 | Contacter | |||
| CLCC RENE HUGUENIN INSTITUT CURIE | 10/04/2025 13:11:58 | Contacter | |||
| HOPITAL FOCH | ANNE CECILE METIVIER | 15/12/2025 08:26:17 | Contacter | ||
| HOPITAL FOCH | ANNE CECILE METIVIER | 01/12/2025 08:26:12 | Contacter | ||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| AP-HP - Hôpital Bichat | Contact (sur clinicalTrials) | ||||
| AP-HP - Hôpital Cochin | Contact (sur clinicalTrials) | ||||
| AP-HP - Hôpital Tenon | Contact (sur clinicalTrials) | ||||
| CENTRE HOSPITALIER SUD FRANCILIEN | Contact (sur clinicalTrials) | ||||
| CHI DE CRETEIL | Contact (sur clinicalTrials) | ||||
| CLCC RENE HUGUENIN INSTITUT CURIE | Contact (sur clinicalTrials) | ||||
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Centre Léon Bérard - 69008 - Lyon 2996944 - France | Contact (sur clinicalTrials) | ||||
| CH Abbeville - 80142 - Abbeville 3038789 - France | Contact (sur clinicalTrials) | ||||
| CHI de Compiègne-Noyon - 60200 - Compiègne 3024066 - France | Contact (sur clinicalTrials) | ||||
| CHR Metz-Thionville - Hôpital de Mercy - Ars-Laquenexy 3036715 - France | Contact (sur clinicalTrials) | ||||
| CHU Grenoble Alpes - 38043 - Grenoble 3014728 - France | Contact (sur clinicalTrials) | ||||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| AP-HP Ambroise Paré - 92100 - Boulogne-Billancourt 3031137 - France | Contact (sur clinicalTrials) | ||||
| CGFL - 21000 - Dijon 3021372 - France | Contact (sur clinicalTrials) | ||||
| CH du Pays d'Aix - 13616 - Aix-en-Provence 3038354 - France | Contact (sur clinicalTrials) | ||||
| CH Henri Duffaut Avignon - 84000 - Avignon 3035681 - France | Contact (sur clinicalTrials) | ||||
| CH Saint-Malo - 35420 - St-Malo 2978640 - France | Contact (sur clinicalTrials) | ||||
| CHD Vendée - 85925 - La Roche-sur-Yon 3006767 - France | Contact (sur clinicalTrials) | ||||
| CHRU Lille - 59000 - Lille 2998324 - France | Contact (sur clinicalTrials) | ||||
| CHU Amiens - Hôpital Sud - 80054 - Amiens 3037854 - France | Contact (sur clinicalTrials) | ||||
| CHU Angers - 49933 - Angers 3037656 - France | Contact (sur clinicalTrials) | ||||
| Clinique des Cèdres - 31700 - Cornebarrieu 3023606 - France | Contact (sur clinicalTrials) | ||||
| Clinique Tessier - 59300 - Valenciennes 2971041 - France | Contact (sur clinicalTrials) | ||||
| Institut Curie - 75005 - Paris 2988507 - France | Contact (sur clinicalTrials) | ||||
| Institut Sainte-Catherine - 84918 - Avignon 3035681 - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
1. Histologically or cytologically proven non-small-cell lung carcinoma (NSCLC)
including NSCLC with oncogene addiction.
2. Stage IV or IIB/IIIC non irradiable (8th classification TNM, UICC 2015)
3. Patient having completed at least one line of chemotherapy in the context of
metastatic disease (or in the context of locoregional disease if the last
chemotherapy was less than 6 months ago).
4. ECOG Performance Status ≥ 2.
5. Age ≥ 18.
6. Written informed consent.
7. Patient capable, according to the investigator, to comply with the requirements of
the study.
Exclusion Criteria:
1. Small Cell Lung Cancer (including mixed forms).
2. Patient with NSCLC for whom a decision has already been made to permanently
discontinue all systemic cancer treatment.
3. Impossible follow up for geographical, social or psychological reason.
4. Inability to answer a questionnaire (language or neurological barrier).
5. Patient under guardianship.
6. Patient being treated in a therapeutic trial.
7. Patient not covered by social security. -